Advertisement
Original Article| Volume 13, ISSUE 5, P839-846, September 2019

Download started.

Ok

Serum concentration of full-length- and carboxy-terminal fragments of endothelial lipase predicts future cardiovascular risks in patients with coronary artery disease

      Highlights

      • A new enzyme-linked immunosorbent assay system for endothelial lipase (EL) was developed.
      • The enzyme-linked immunosorbent assay could detect both full-length and C-terminal fragments of EL (total EL).
      • Total EL mass was inversely correlated with high-density lipoprotein cholesterol in patients with coronary artery disease.
      • Total EL could be a predictor for major cardiovascular events in patient with coronary artery disease.

      Background

      Endothelial lipase (EL), a regulator of plasma high-density lipoprotein cholesterol (HDL-C), is secreted as a 68-kDa mature glycoprotein, and then cleaved by proprotein convertases. However, the clinical significance of the circulating EL fragments remains unclear.

      Objective

      The objective of this study was to analyze the impact of serum EL fragments on HDL-C levels and major adverse cardiovascular events (MACE).

      Methods

      Using novel monoclonal antibodies (RC3A6) against carboxy-terminal EL protein, we have established a new enzyme-linked immunosorbent assay (ELISA) system, which can detect both full-length EL protein (full EL) and carboxy-terminal truncated fragments (total EL) in serum. The previous sandwich ELISA detected only full EL. The full and total EL mass were measured in 556 patients with coronary artery disease. Among them, 272 patients who underwent coronary intervention were monitored for 2 years for MACE.

      Results

      There was a significant correlation between serum full and total EL mass (R = 0.45, P < .0001). However, the total EL mass showed a stronger inverse correlation with serum HDL-cholesterol concentration than the full EL mass (R = −0.17 vs −0.02). Kaplan-Meier analysis documented an association of serum total EL mass and MACE (log-rank P = .037). When an optimal cutoff value was set at 96.23 ng/mL, total EL mass was an independent prognostic factor for MACE in the Cox proportional hazard model (HR; 1.75, 95% CI; 1.10–2.79, P = .018).

      Conclusion

      Serum total EL mass could be a predictor for MACE in patients with coronary artery disease. This novel ELISA will be useful for further clarifying the impact of EL on HDL metabolism and atherosclerosis.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gordon T.
        • Castelli W.P.
        • Hjortland M.C.
        • Kannel W.B.
        • Dawber T.R.
        High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.
        Am J Med. 1977; 62: 707-714
        • Barter P.J.
        • Caulfield M.
        • Eriksson M.
        • et al.
        Effects of torcetrapib in patients at high risk for coronary events.
        N Engl J Med. 2007; 357: 2109-2122
        • Boden W.E.
        • Probstfield J.L.
        • Anderson T.
        • et al.
        • AIM-HIGH Investigators
        Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
        N Engl J Med. 2011; 365: 2255-2267
        • Karathanasis S.K.
        • Freeman L.A.
        • Gordon S.M.
        • Remaley A.T.
        The changing face of hdl and the best way to measure it.
        Clin Chem. 2017; 63: 196-210
        • Rosenson R.S.
        The high-density lipoprotein puzzle: why classic epidemiology, genetic epidemiology, and clinical trials conflict?.
        Arterioscler Thromb Vasc Biol. 2016; 36: 777-782
        • Jaye M.
        • Lynch K.J.
        • Krawiec J.
        • et al.
        A novel endothelial-derived lipase that modulates HDL metabolism.
        Nat Genet. 1999; 21: 424-428
        • Hirata K.
        • Dichek H.L.
        • Cioffi J.A.
        • et al.
        Cloning of a unique lipase from endothelial cells extends the lipase gene family.
        J Biol Chem. 1999; 274: 14170-14175
        • Ishida T.
        • Choi S.
        • Kundu R.K.
        • et al.
        Endothelial lipase is a major determinant of HDL level.
        J Clin Invest. 2003; 111: 347-355
        • Kojima Y.
        • Ishida T.
        • Sun L.
        • et al.
        Pitavastatin decreases expression of endothelial lipase both in vitro and in vivo.
        Cardiovasc Res. 2010; 87: 385-393
        • Badellino K.O.
        • Wolfe M.L.
        • Reilly M.P.
        • Rader D.J.
        Endothelial lipase is increased in vivo by inflammation in humans.
        Circulation. 2008; 117: 678-685
        • Sun L.
        • Ishida T.
        • Miyashita K.
        • et al.
        Plasma activity of endothelial lipase impacts high-density lipoprotein metabolism and coronary risk factors in humans.
        J Atheroscler Thromb. 2014; 21: 313-321
        • Singaraja R.R.
        • Sivapalaratnam S.
        • Hovingh K.
        • et al.
        The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans.
        Circ Cardiovasc Genet. 2013; 6: 54-62
        • Edmondson A.C.
        • Brown R.J.
        • Kathiresan S.
        • et al.
        Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans.
        J Clin Invest. 2009; 119: 1042-1050
        • Voight B.F.
        • Peloso G.M.
        • Orho-Melander M.
        • et al.
        Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.
        Lancet. 2012; 380: 572-580
        • Jin W.
        • Wang X.
        • Millar J.S.
        • et al.
        Hepatic proprotein convertases modulate HDL metabolism.
        Cell Metab. 2007; 6: 129-136
        • Griffon N.
        • Jin W.
        • Petty T.J.
        • et al.
        Identification of the active form of endothelial lipase, a homodimer in a head-to-tail conformation.
        J Biol Chem. 2009; 28: 23322-23330
        • Ishida T.
        • Miyashita K.
        • Shimizu M.
        • et al.
        ELISA system for human endothelial lipase.
        Clin Chem. 2012; 58: 1656-1664
        • Miyashita K.
        • Nakajima K.
        • Fukamachi I.
        • et al.
        A new enzyme-linked immunosorbent assay system for human serum hepatic triglyceride lipase.
        J Lipid Res. 2017; 58: 1591-1597
        • Mori K.
        • Ishida T.
        • Yasuda T.
        • et al.
        Serum trans-fatty acid concentration is elevated in young patients with coronary artery disease in Japan.
        Circ J. 2015; 79: 2017-2025
        • Ishida T.
        • Choi S.Y.
        • Kundu R.K.
        • et al.
        Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice.
        J Biol Chem. 2004; 279: 45085-45092
        • Sun L.
        • Ishida T.
        • Okada T.
        • et al.
        Expression of endothelial lipase correlates with the size of neointima in a murine model of vascular remodeling.
        J Atheroscler Thromb. 2012; 19: 1110-1127
        • Wang C.
        • Nishijima K.
        • Kitajima S.
        • et al.
        Increased hepatic expression of endothelial lipase inhibits cholesterol diet-induced hypercholesterolemia and atherosclerosis in transgenic rabbits.
        Arterioscler Thromb Vasc Biol. 2017; 37: 1282-1289
        • Ko K.W.
        • Paul A.
        • Ma K.
        • Li L.
        • Chan L.
        Endothelial lipase modulates HDL but has no effect on atherosclerosis development in apoE-/- and LDLR-/- mice.
        J Lipid Res. 2005; 46: 2586-2594
        • Badellino K.O.
        • Wolfe M.L.
        • Reilly M.P.
        • Rader D.J.
        Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis.
        PLoS Med. 2006; 3: e22
        • Robert J.
        • Lehner M.
        • Frank S.
        • Perisa D.
        • von Eckardstein A.
        • Rohrer L.
        Interleukin 6 stimulates endothelial binding and transport of high-density lipoprotein through induction of endothelial lipase.
        Arterioscler Thromb Vasc Biol. 2013; 33: 2699-2706
        • Do R.
        • Willer C.J.
        • Schmidt E.M.
        • et al.
        Common variants associated with plasma triglycerides and risk for coronary artery disease.
        Nat Genet. 2013; 45: 1345-1352
        • Nagao M.
        • Nakajima H.
        • Ryuji T.
        • Hirata K.
        • Ishida T.
        Cardioprotective effects of high-density lipoprotein beyond its anti-atherogenic action.
        J Atheroscler Thromb. 2018; 25: 985-993
        • Rohatgi A.
        • Khera A.
        • Berry J.D.
        • et al.
        HDL cholesterol efflux capacity and incident cardiovascular events.
        N Engl J Med. 2014; 371: 2383-2393
        • Khera A.V.
        • Cuchel M.
        • de la Llera-Moya M.
        • et al.
        Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.
        N Engl J Med. 2011; 364: 127-135
        • Schilcher I.
        • Kern S.
        • Hrzenjak A.
        • et al.
        Impact of endothelial lipase on cholesterol efflux capacity of serum and high-density lipoprotein.
        Sci Rep. 2017; 7: 12485
        • Hara T.
        • Ishida T.
        • Kojima Y.
        • et al.
        Targeted deletion of endothelial lipase increases HDL particles with anti-inflammatory properties both in vitro and in vivo.
        J Lipid Res. 2011; 52: 57-67
        • Tanaka N.
        • Irino Y.
        • Shinohara M.
        • et al.
        Eicosapentaenoic acid-enriched high-density lipoproteins exhibit anti-atherogenic properties.
        Circ J. 2018; 82: 596-601
        • Baker P.W.
        • Rye K.A.
        • Gamble J.R.
        • Vadas M.A.
        • Barter P.J.
        Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression.
        J Lipid Res. 2000; 41: 1261-1267
        • Hirata K.
        • Ishida T.
        • Matsushita H.
        • Tsao P.S.
        • Quertermous T.
        Regulated expression of endothelial cell-derived lipase.
        Biochem Biophys Res Commun. 2000; 272: 90-93